Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up on Analyst Upgrade

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) shares gapped up prior to trading on Tuesday after Piper Sandler raised their price target on the stock from $35.00 to $40.00. The stock had previously closed at $15.79, but opened at $17.16. Day One Biopharmaceuticals shares last traded at $15.69, with a volume of 6,403 shares trading hands.

Separately, Wedbush lifted their price target on Day One Biopharmaceuticals from $32.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, June 13th.

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $16.26, for a total value of $813,000.00. Following the completion of the transaction, the insider now owns 1,316,718 shares in the company, valued at approximately $21,409,834.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Institutional investors and hedge funds have recently made changes to their positions in the business. Citigroup Inc. acquired a new position in shares of Day One Biopharmaceuticals in the 3rd quarter valued at approximately $30,000. Royal Bank of Canada acquired a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at approximately $33,000. Morgan Stanley acquired a new stake in Day One Biopharmaceuticals in the second quarter worth $54,000. Metropolitan Life Insurance Co NY acquired a new stake in Day One Biopharmaceuticals in the third quarter worth $86,000. Finally, California State Teachers Retirement System increased its position in Day One Biopharmaceuticals by 58.6% in the first quarter. California State Teachers Retirement System now owns 9,687 shares of the company’s stock worth $96,000 after buying an additional 3,581 shares during the period. 79.02% of the stock is currently owned by institutional investors.

The company has a 50 day moving average price of $9.18 and a 200-day moving average price of $12.22.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last announced its earnings results on Thursday, May 12th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.09). On average, sell-side analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.05 earnings per share for the current fiscal year.

Day One Biopharmaceuticals Company Profile (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.